128 related articles for article (PubMed ID: 21392103)
1. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.
Zeiner P; Gjevik E; Weidle B
Acta Paediatr; 2011 Sep; 100(9):1258-61. PubMed ID: 21392103
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
6. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
[TBL] [Abstract][Full Text] [Related]
7. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
8. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study.
Fernández-Jaén A; Fernández-Mayoralas DM; Calleja-Pérez B; Muñoz-Jareño N; Campos Díaz Mdel R; López-Arribas S
J Atten Disord; 2013 Aug; 17(6):497-505. PubMed ID: 22366240
[TBL] [Abstract][Full Text] [Related]
14. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
[TBL] [Abstract][Full Text] [Related]
15. Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder.
Barry RJ; Clarke AR; Hajos M; McCarthy R; Selikowitz M; Bruggemann JM
Neuropharmacology; 2009 Dec; 57(7-8):702-7. PubMed ID: 19698723
[TBL] [Abstract][Full Text] [Related]
16. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
Biederman J; Gao H; Rogers AK; Spencer TJ
Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
[TBL] [Abstract][Full Text] [Related]
17. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
Shang CY; Gau SS
J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]